4D Molecular Therapeutics (FDMT) Cash from Investing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Cash from Investing Activities for 7 consecutive years, with $68.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 115.63% year-over-year to $68.9 million; the TTM figure through Mar 2026 stood at -$56.0 million (down 674.9% YoY), while the FY2025 annual figure was -$93.0 million, up 69.26% from the prior year.
• Cash from Investing Activities rose to $68.9 million in Q1 2026 per FDMT's latest filing, from -$128.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $68.9 million in Q1 2026 and bottomed at -$263.3 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$13.4 million across 5 years, with a median of $15.4 million in 2022.
• On a YoY basis, Cash from Investing Activities climbed as much as 7897.56% in 2022 and fell as far as 8328.35% in 2022.
• 4D Molecular Therapeutics' Cash from Investing Activities stood at -$35.8 million in 2022, then soared by 81.32% to -$6.7 million in 2023, then jumped by 205.64% to $7.1 million in 2024, then tumbled by 1925.29% to -$128.8 million in 2025, then jumped by 153.46% to $68.9 million in 2026.
• Business Quant data shows FDMT's Cash from Investing Activities at $68.9 million in Q1 2026, -$128.8 million in Q4 2025, and $17.8 million in Q3 2025.